Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Tris Pharma Inc Drug Patent Portfolio

Tris Pharma Inc owns 7 orange book drugs protected by 12 US patents with Onyda Xr having the least patent protection, holding only 2 patents. And Dyanavel Xr with maximum patent protection, holding 7 patents. Given below is the list of Tris Pharma Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11918689 Liquid clonidine extended release composition 28 Jul, 2041
Active
US11590081 Extended release amphetamine tablets 24 Sep, 2038
Active
US11590228 Extended release amphetamine compositions 07 Sep, 2036
Active
US8062667 Modified release formulations containing drug-ion exchange resin complexes 29 Mar, 2029
Active
US10086087 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
Active
US8597684 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
Active
US8747902 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
Active
US8883217 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
Active
US9675703 Modified release formulations containing drug - ion exchange resin complexes 15 Mar, 2027
Active
US8337890 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
Active
US9675704 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
Active
US8790700 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
Active


Given below is the list of recent legal activities going on the following drug patents of Tris Pharma Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 21 May, 2024 US8337890
Payment of Maintenance Fee, 12th Year, Large Entity 21 May, 2024 US8337890
Payment of Maintenance Fee, 12th Year, Large Entity 21 May, 2024 US8337890
Payment of Maintenance Fee, 12th Year, Large Entity 21 May, 2024 US8337890
Post Issue Communication - Certificate of Correction 06 Nov, 2023 US11590228
Email Notification
Critical
29 Sep, 2023 US11590228
Mail Pub Notice re 312 amendment 29 Sep, 2023 US11590228
Post Issue Communication - Certificate of Correction Denied 27 Sep, 2023 US11590228
POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION 26 Sep, 2023 US11590228
Payment of Maintenance Fee, 12th Year, Large Entity 10 May, 2023 US8062667 (Litigated)
Patent Issue Date Used in PTA Calculation
Critical
28 Feb, 2023 US11590228
Patent Issue Date Used in PTA Calculation
Critical
28 Feb, 2023 US11590081
Recordation of Patent Grant Mailed
Critical
28 Feb, 2023 US11590081
Recordation of Patent Grant Mailed
Critical
28 Feb, 2023 US11590081
Recordation of Patent Grant Mailed
Critical
28 Feb, 2023 US11590228


Tris Pharma Inc's Family Patents

Tris Pharma Inc drugs have patent protection in a total of 14 countries. It has a significant patent presence in the US with 59.5% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Tris Pharma Inc Drug List

Given below is the complete list of Tris Pharma Inc's drugs and the patents protecting them.


1. Dyanavel Xr

Dyanavel Xr is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11590228 Extended release amphetamine compositions 07 Sep, 2036
(11 years from now)
Active
US8062667 Modified release formulations containing drug-ion exchange resin complexes 29 Mar, 2029
(3 years from now)
Active
US10086087 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active
US8597684 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active
US8747902 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active
US8883217 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active
US9675703 Modified release formulations containing drug - ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dyanavel Xr's drug page


2. Dyanavel Xr 10

Dyanavel Xr 10 is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11590081 Extended release amphetamine tablets 24 Sep, 2038
(13 years from now)
Active
US8337890 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active
US8747902 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active
US9675704 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dyanavel Xr 10's drug page


3. Dyanavel Xr 15

Dyanavel Xr 15 is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11590081 Extended release amphetamine tablets 24 Sep, 2038
(13 years from now)
Active
US8337890 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active
US8747902 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active
US9675704 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dyanavel Xr 15's drug page


4. Dyanavel Xr 20

Dyanavel Xr 20 is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11590081 Extended release amphetamine tablets 24 Sep, 2038
(13 years from now)
Active
US8337890 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active
US8747902 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active
US9675704 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dyanavel Xr 20's drug page


5. Dyanavel Xr 5

Dyanavel Xr 5 is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11590081 Extended release amphetamine tablets 24 Sep, 2038
(13 years from now)
Active
US8337890 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active
US8747902 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active
US9675704 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dyanavel Xr 5's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Onyda Xr

Onyda Xr is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11918689 Liquid clonidine extended release composition 28 Jul, 2041
(16 years from now)
Active
US8062667 Modified release formulations containing drug-ion exchange resin complexes 29 Mar, 2029
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onyda Xr's drug page


7. Tuzistra Xr

Tuzistra Xr is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8062667 Modified release formulations containing drug-ion exchange resin complexes 29 Mar, 2029
(3 years from now)
Active
US8790700 Modified release formulations containing drug-ion exchange resin complexes 15 Mar, 2027
(1 year, 10 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tuzistra Xr's drug page